We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
Read MoreHide Full Article
Key Takeaways
Agenus shares fell 19.4% in a month after missing Q1 2026 earnings and revenue estimates.
AGEN launched the phase III BATTMAN study for BOT/BAL in MSS metastatic colorectal cancer.
Agenus expanded BOT/BAL access globally and strengthened liquidity via the Zydus deal.
Shares of Agenus (AGEN - Free Report) have lost 19.4% in the past month, likely due to the disappointing first-quarter 2026 results reported last week, as the company missed both earnings and revenue estimates by a significant margin.
However, quarterly results offer only a snapshot of performance, while investors tend to focus more closely on broader business fundamentals and growth prospects. Let’s explore the company’s fundamentals to better understand how to play the stock amid the recent decline.
BOT/BAL Program Remains Key Value Driver for Agenus
Agenus continues to make meaningful progress with its lead immuno-oncology combination, botensilimab plus balstilimab (BOT/BAL), which remains the company’s primary long-term growth driver. The company has increasingly aligned its business strategy around the program following its 2024 strategic restructuring.
The biggest recent milestone was the initiation of patient enrollment in the global phase III BATTMAN study. The study is evaluating BOT/BAL in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a setting in which currently available checkpoint inhibitors have historically shown limited benefit. Agenus is conducting the study in partnership with the Canadian Cancer Trials Group across multiple international regions.
The program has also generated encouraging clinical data so far. Per Agenus, BOT/BAL has been evaluated in roughly 1,300 patients across more than nine tumor types. Last year, the company reported long-term follow-up data from an early-stage study in heavily pretreated MSS mCRC, in which treatment achieved about 42% two-year overall survival and a median overall survival of nearly 21 months. According to Agenus, these findings form part of the broader clinical evidence supporting its plans to seek accelerated approval in the United States and conditional approval in the European Union.
Beyond clinical development, Agenus is also expanding physician access to BOT/BAL through regulatory-authorized pathways in select countries. France has broadened reimbursed access for eligible patients under its AAC framework, while named-patient programs continue to expand across parts of Europe and Latin America. The company has also started recognizing revenues from these programs.
Importantly, Agenus strengthened its manufacturing and liquidity position earlier this year through its collaboration with Zydus Lifesciences. The transaction provided upfront capital, dedicated biologics manufacturing capacity and potential future milestone payments tied to BOT/BAL production activities.
Competitive Pressure in Targeted Markets
Despite its promising pipeline progress, Agenus operates in a highly competitive oncology landscape dominated by Big Pharma. BOT/BAL competes against well-established immunotherapies such as Merck’s (MRK - Free Report) Keytruda and Bristol Myers’ (BMY - Free Report) Opdivo and Yervoy. These drugs have strong commercial positions across multiple cancer indications, making it difficult for smaller biotech companies to establish market share.
Beyond having approved therapies, these large pharmaceutical companies possess significantly greater financial resources, extensive global commercial infrastructure and well-established supply chains. Their long-standing presence in oncology gives them deep clinical development experience and strong relationships with physicians and treatment centers, which could make market penetration more challenging for newer entrants like Agenus.
AGEN’s Stock Performance, Valuation & Estimates
Despite the recent weakness, shares of Agenus have outperformed both the industry and the broader sector on a year-to-date basis. However, the stock has lagged the S&P 500 index during the same period, as seen in the chart below.
AGEN Stock Performance
Image Source: Zacks Investment Research
The company is currently trading at a discount to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 0.96 times forward 12-month sales, below the industry average of 1.96 times.
Image Source: Zacks Investment Research
Estimate revisions for Agenus’ 2026 and 2027 bottom-line have been mixed over the past 30 days.
Image Source: Zacks Investment Research
How to Play AGEN Stock?
Agenus continues to advance its BOT/BAL program through late-stage development while also expanding early-access pathways internationally. Encouraging survival data in MSS colorectal cancer and the ongoing BATTMAN study support the company’s long-term growth potential. Additionally, the recent Zydus collaboration has strengthened Agenus’ manufacturing and liquidity position.
However, the company still faces considerable risks, including intense competition from pharma giants, regulatory uncertainty and continued financial pressure typical of small-cap biotech companies.
Given the balanced risk-reward profile, investors may prefer to remain cautious on the stock at current levels. Agenus currently carries a Zacks Rank #3 (Hold), and the stock appears better suited for long-term investors with a higher risk tolerance.
View the Zacks #1 Rank List
Image: Bigstock
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
Key Takeaways
Shares of Agenus (AGEN - Free Report) have lost 19.4% in the past month, likely due to the disappointing first-quarter 2026 results reported last week, as the company missed both earnings and revenue estimates by a significant margin.
However, quarterly results offer only a snapshot of performance, while investors tend to focus more closely on broader business fundamentals and growth prospects. Let’s explore the company’s fundamentals to better understand how to play the stock amid the recent decline.
BOT/BAL Program Remains Key Value Driver for Agenus
Agenus continues to make meaningful progress with its lead immuno-oncology combination, botensilimab plus balstilimab (BOT/BAL), which remains the company’s primary long-term growth driver. The company has increasingly aligned its business strategy around the program following its 2024 strategic restructuring.
The biggest recent milestone was the initiation of patient enrollment in the global phase III BATTMAN study. The study is evaluating BOT/BAL in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a setting in which currently available checkpoint inhibitors have historically shown limited benefit. Agenus is conducting the study in partnership with the Canadian Cancer Trials Group across multiple international regions.
The program has also generated encouraging clinical data so far. Per Agenus, BOT/BAL has been evaluated in roughly 1,300 patients across more than nine tumor types. Last year, the company reported long-term follow-up data from an early-stage study in heavily pretreated MSS mCRC, in which treatment achieved about 42% two-year overall survival and a median overall survival of nearly 21 months. According to Agenus, these findings form part of the broader clinical evidence supporting its plans to seek accelerated approval in the United States and conditional approval in the European Union.
Beyond clinical development, Agenus is also expanding physician access to BOT/BAL through regulatory-authorized pathways in select countries. France has broadened reimbursed access for eligible patients under its AAC framework, while named-patient programs continue to expand across parts of Europe and Latin America. The company has also started recognizing revenues from these programs.
Importantly, Agenus strengthened its manufacturing and liquidity position earlier this year through its collaboration with Zydus Lifesciences. The transaction provided upfront capital, dedicated biologics manufacturing capacity and potential future milestone payments tied to BOT/BAL production activities.
Competitive Pressure in Targeted Markets
Despite its promising pipeline progress, Agenus operates in a highly competitive oncology landscape dominated by Big Pharma. BOT/BAL competes against well-established immunotherapies such as Merck’s (MRK - Free Report) Keytruda and Bristol Myers’ (BMY - Free Report) Opdivo and Yervoy. These drugs have strong commercial positions across multiple cancer indications, making it difficult for smaller biotech companies to establish market share.
Beyond having approved therapies, these large pharmaceutical companies possess significantly greater financial resources, extensive global commercial infrastructure and well-established supply chains. Their long-standing presence in oncology gives them deep clinical development experience and strong relationships with physicians and treatment centers, which could make market penetration more challenging for newer entrants like Agenus.
AGEN’s Stock Performance, Valuation & Estimates
Despite the recent weakness, shares of Agenus have outperformed both the industry and the broader sector on a year-to-date basis. However, the stock has lagged the S&P 500 index during the same period, as seen in the chart below.
AGEN Stock Performance
Image Source: Zacks Investment Research
The company is currently trading at a discount to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 0.96 times forward 12-month sales, below the industry average of 1.96 times.
Image Source: Zacks Investment Research
Estimate revisions for Agenus’ 2026 and 2027 bottom-line have been mixed over the past 30 days.
Image Source: Zacks Investment Research
How to Play AGEN Stock?
Agenus continues to advance its BOT/BAL program through late-stage development while also expanding early-access pathways internationally. Encouraging survival data in MSS colorectal cancer and the ongoing BATTMAN study support the company’s long-term growth potential. Additionally, the recent Zydus collaboration has strengthened Agenus’ manufacturing and liquidity position.
However, the company still faces considerable risks, including intense competition from pharma giants, regulatory uncertainty and continued financial pressure typical of small-cap biotech companies.
Given the balanced risk-reward profile, investors may prefer to remain cautious on the stock at current levels. Agenus currently carries a Zacks Rank #3 (Hold), and the stock appears better suited for long-term investors with a higher risk tolerance.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.